Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

ImmunityBio

Status: Active, not recruiting

Conditions: Non Muscle Invasive Bladder Cancer

Treatments: Drug: N803 plus Bacillus Calmette-Guerin (BCG)

Study type: Observational

Funder types: Industry

Identifiers

NCT05981131

QUILT-205

Details and patient eligibility

About

The purpose of this clinical trial is to obtain long-term follow-up information and status of bladder cancer for patients who received study treatment in the QUILT-2.005 study.

Full description

All 9 subjects that completed QUILT-2.005 phase 1b are planned to be enrolled in this study.

Thus, the maximum enrollment for this study is 9 subjects. All enrolled subjects will be followed every 12 months for life, or until withdrawal of consent, or if the Sponsor closes the study.

Enrollment: 6 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Enrolled and treated with intravesical N-803 plus BCG in the phase 1b portion of QUILT-2.005.

Exclusion criteria

• Not applicable